- Home
- CIO vs GNFT Comparison
CIO vs GNFT Comparison
Compare CIO & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIO
- GNFT
- Stock Information
- Founded
- CIO 2013
- GNFT 1999
- Country
- CIO Canada
- GNFT France
- Employees
- CIO N/A
- GNFT N/A
- Industry
- CIO Real Estate Investment Trusts
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIO Real Estate
- GNFT Health Care
- Exchange
- CIO Nasdaq
- GNFT Nasdaq
- Market Cap
- CIO 230.9M
- GNFT 190.6M
- IPO Year
- CIO 2014
- GNFT 2019
- Fundamental
- Price
- CIO $5.35
- GNFT $3.81
- Analyst Decision
- CIO
- GNFT Strong Buy
- Analyst Count
- CIO 0
- GNFT 1
- Target Price
- CIO N/A
- GNFT $13.00
- AVG Volume (30 Days)
- CIO 235.1K
- GNFT 7.8K
- Earning Date
- CIO 02-20-2025
- GNFT 09-19-2024
- Dividend Yield
- CIO 7.49%
- GNFT N/A
- EPS Growth
- CIO N/A
- GNFT N/A
- EPS
- CIO N/A
- GNFT 0.47
- Revenue
- CIO $173,528,000.00
- GNFT $86,225,222.00
- Revenue This Year
- CIO N/A
- GNFT $155.44
- Revenue Next Year
- CIO $0.90
- GNFT N/A
- P/E Ratio
- CIO N/A
- GNFT $7.69
- Revenue Growth
- CIO N/A
- GNFT 175.45
- 52 Week Low
- CIO $4.02
- GNFT $3.31
- 52 Week High
- CIO $6.50
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- CIO 40.31
- GNFT 32.66
- Support Level
- CIO $5.20
- GNFT $3.63
- Resistance Level
- CIO $5.51
- GNFT $3.76
- Average True Range (ATR)
- CIO 0.19
- GNFT 0.12
- MACD
- CIO -0.05
- GNFT 0.04
- Stochastic Oscillator
- CIO 4.43
- GNFT 18.77
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. The company owns office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.